Filing Details
- Accession Number:
- 0001209191-21-024288
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-04-01 19:37:52
- Reporting Period:
- 2021-03-30
- Accepted Time:
- 2021-04-01 19:37:52
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1812364 | Relay Therapeutics Inc. | RLAY | Biological Products, (No Disgnostic Substances) (2836) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1818261 | Thomas Catinazzo | C/O Relay Therapeutics, Inc. 399 Binney Street, 2Nd Floor Cambridge MA 02139 | Senior Vice President, Finance | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2021-03-30 | 22,500 | $4.12 | 22,500 | No | 4 | M | Direct | |
Common Stock | Disposition | 2021-03-30 | 22,500 | $35.00 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2021-03-30 | 22,500 | $0.00 | 22,500 | $4.12 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
107,043 | 2028-04-09 | No | 4 | M | Direct |
Footnotes
- The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2020.
- Twenty-five percent (25%) of the shares underlying this option vested on April 9, 2019 and the remainder shall vest in equal quarterly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.